63: Crizotinib for ALK rearrangement in non small cell lung cancerS. Merrick, Sunita Ghosh, E. McMunagle et al.|Lung Cancer|2017Cited by 0
72: Treatment outcomes with tyrosine kinase inhibitors in patients with uncommon EGFR mutations in non-small cell lung cancerSarah Hunter, Eleni Karapanagiotou, Guillermina Nickless et al.|Lung Cancer|2017Cited by 0